Related Experiment Videos
[Current and future approaches to therapy for multiple myeloma]
1Laboratory Medicine, Tokyo Medical and Dental University Faculty of Medicine, Japan.
Gan to Kagaku Ryoho. Cancer & Chemotherapy
|January 1, 1995
Summary
Multiple myeloma, a plasma cell cancer, has limited survival despite standard therapy. Newer treatments like chemotherapy, interferon, and bone marrow transplant offer improved prognosis for this hematologic malignancy.
Area of Science:
- Hematologic oncology
- Cancer biology
Context:
- Multiple myeloma is a plasma cell malignancy comprising 10% of hematologic cancers.
- Characterized by uncontrolled plasma cell growth in bone marrow, leading to bone destruction, renal impairment, and infections.
- Current standard therapy (melphalan and prednisolone) offers limited survival (median 2.5-3 years).
Purpose:
- To review novel therapeutic strategies for multiple myeloma.
- To discuss combination chemotherapy, interferon therapy, and bone marrow transplantation.
- To explore future treatment directions based on disease biology.
Summary:
- Multiple myeloma involves malignant plasma cell proliferation with distinct clinical features.
- Established treatments have shown limited efficacy, necessitating advanced therapeutic options.
- Novel approaches including chemotherapy, interferon, and bone marrow transplantation are explored.
Impact:
- Advances in multiple myeloma treatment can improve patient survival and quality of life.
- Understanding disease biology is crucial for developing targeted and effective therapies.
- This review highlights promising strategies to overcome the challenges of intractable multiple myeloma.